Your browser is no longer supported. Please, upgrade your browser.
Settings
CGEN Compugen Ltd. daily Stock Chart
CGEN [NASD]
Compugen Ltd.
Index- P/E- EPS (ttm)-0.43 Insider Own12.00% Shs Outstand61.82M Perf Week6.78%
Market Cap223.79M Forward P/E- EPS next Y-0.67 Insider Trans0.00% Shs Float57.25M Perf Month21.07%
Income-22.50M PEG- EPS next Q-0.19 Inst Own20.10% Short Float5.61% Perf Quarter13.48%
Sales17.80M P/S12.57 EPS this Y-16.90% Inst Trans-16.57% Short Ratio20.79 Perf Half Y13.12%
Book/sh0.67 P/B5.40 EPS next Y-52.30% ROA-50.10% Target Price9.00 Perf Year16.77%
Cash/sh- P/C- EPS next 5Y- ROE-65.10% 52W Range2.00 - 5.00 Perf YTD66.82%
Dividend- P/FCF- EPS past 5Y-13.80% ROI- 52W High-27.60% Beta2.54
Dividend %- Quick Ratio4.60 Sales past 5Y- Gross Margin94.20% 52W Low81.00% ATR0.19
Employees101 Current Ratio4.60 Sales Q/Q- Oper. Margin- RSI (14)59.06 Volatility6.67% 5.37%
OptionableYes Debt/Eq0.00 EPS Q/Q71.80% Profit Margin- Rel Volume0.75 Prev Close3.74
ShortableYes LT Debt/Eq0.00 EarningsFeb 26 BMO Payout- Avg Volume154.33K Price3.62
Recom- SMA203.35% SMA5017.48% SMA2007.75% Volume117,301 Change-3.21%
Mar-29-18Initiated Oppenheimer Outperform
Feb-01-16Resumed Oppenheimer Outperform
Oct-15-15Initiated FBR Capital Outperform $14
Apr-23-15Resumed Jefferies Buy $11
Apr-21-15Initiated Oppenheimer Outperform $11
Feb-07-14Initiated MLV & Co Buy $14
Dec-28-09Reiterated Cantor Fitzgerald Buy $5 → $12
Jul-29-09Initiated Cantor Fitzgerald Buy $6.50
Feb-14-19 07:00AM  Compugen Fourth Quarter and Full Year 2018 Conference Call Scheduled for Tuesday, February 26, 2019 at 8:30 AM ET PR Newswire
Jan-22-19 07:00AM  Compugen Announces Publication of Two Peer-Reviewed Papers Demonstrating the Role of PVRIG as a Novel Immune Checkpoint for Cancer Immunotherapy PR Newswire +12.62%
Jan-16-19 07:07AM  How Much Of Compugen Ltd. (NASDAQ:CGEN) Do Institutions Own? Simply Wall St.
Jan-14-19 07:00AM  Compugen's Phase 1 Trial of COM701 Featured as a Trial-in-Progress at The ASCO-SITC Clinical Immuno-Oncology Symposium PR Newswire
Nov-23-18 08:20AM  New Research Coverage Highlights Vulcan Materials, Cimpress N.V, Asterias Biotherapeutics, ElectraMeccanica Vehicles, Compugen, and China HGS Real Estate Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-13-18 07:00AM  Compugen Announces Issuance of U.S. Patent for COM902, Its TIGIT Antibody Product Candidate for Cancer Immunotherapy PR Newswire
Nov-07-18 08:20AM  Compugen (CGEN) Reports Q3 Loss Zacks +14.29%
07:20AM  Compugen: 3Q Earnings Snapshot Associated Press
07:00AM  Compugen Reports Third Quarter 2018 Results PR Newswire
Nov-05-18 05:35AM  Compugen Ltd. (CGEN) Sees Hammer Chart Pattern: Time to Buy? Zacks
Oct-24-18 07:15AM  Compugen Third Quarter 2018 Conference Call Scheduled for Wednesday, November 7, 2018 at 8:30 AM ET PR Newswire -7.49%
Oct-12-18 03:09PM  Don't Fixate On Market Woes, Just Make Your Trades Benzinga
10:25AM  Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal Zacks
09:30AM  Bristol-Myers Inks Deal and Invests $12 Million in Compugen Zacks
Oct-11-18 07:32AM  Compugen's stock shoots up after Bristol-Myers to pay 52% premium for equity stake MarketWatch +7.69%
07:00AM  Bristol-Myers to invest in Compugen, collaborate in clinical trials Reuters
06:59AM  Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors PR Newswire
Sep-20-18 07:00AM  Compugen Announces Clinical Milestone Payment in Cancer Immunotherapy Collaboration With Bayer Following Dosing of First Patient in BAY 1905254 Phase 1 Trial PR Newswire
Sep-14-18 01:27PM  Should You Have Compugen Ltds (NASDAQ:CGEN) In Your Portfolio? Simply Wall St.
Sep-07-18 07:00AM  Compugen Announces First Patient Dosed with COM701, a First-in-Class Cancer Immunotherapy Antibody, in Phase 1 Clinical Trial PR Newswire
Sep-05-18 07:00AM  Compugen Announces Appointment of Dr. Jean-Pierre Bizzari to its Board of Directors PR Newswire
Aug-01-18 07:28AM  Compugen: 2Q Earnings Snapshot Associated Press
07:00AM  Compugen Reports Second Quarter 2018 Results PR Newswire
06:30AM  Compugen Ltd. to Host Earnings Call ACCESSWIRE
Jul-18-18 07:00AM  Compugen Second Quarter 2018 Conference Call Scheduled for Wednesday, August 1, 2018 at 8:30 AM ET PR Newswire
Jul-02-18 09:10AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:05AM  Compugen Welcomes FDA Clearance of Bayer's IND Application for BAY 1905254 PR Newswire
07:00AM  Compugen Announces FDA Clearance of IND Application for COM701, a First-in-class Immuno-Oncology Therapeutic Antibody PR Newswire
Jun-27-18 12:38PM  When Should You Buy Compugen Ltd (NASDAQ:CGEN)? Simply Wall St. -8.33%
Jun-15-18 07:00AM  Compugen Announces $21 Million Registered Direct Offering of Ordinary Shares and Warrants PR Newswire
Jun-11-18 07:00AM  Compugen Announces the Appointment of New Board Members PR Newswire
May-16-18 08:53AM  Market Has Not Yet Noticed Potential in Compugen; Have You? Zacks
May-09-18 07:58AM  Compugen: 1Q Earnings Snapshot Associated Press
07:00AM  Compugen Reports First Quarter 2018 Results PR Newswire
May-02-18 07:14PM  Compugen Ltd (NASDAQ:CGEN): Should The Recent Earnings Drop Worry You? Simply Wall St.
Apr-30-18 07:00AM  Compugen First Quarter 2018 Conference Call Scheduled for Wednesday, May 9, 2018 at 10:00 AM ET PR Newswire
Apr-27-18 07:24AM  Compugen Reports on Status of Investigational New Drug Application for COM701, a First-in-Class Immuno-Oncology Therapeutic Antibody PR Newswire -7.79%
Apr-19-18 07:40AM  Blog Exposure - Preclinical Data Presented by Bayer at AACR Highlights Compugens BAY 1905254 Efficacy in Cancer Immunotherapy ACCESSWIRE
Apr-17-18 07:00AM  Preclinical Data Presented by Bayer at AACR Highlights BAY 1905254, Formerly the CGEN-15001T Program, Efficacy in Cancer Immunotherapy PR Newswire
Apr-03-18 01:00AM  [$$] AstraZeneca receives regulatory boost for oncology drugs Financial Times
Apr-02-18 10:04AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:25AM  Compugen Announces Exclusive License Agreement With MedImmune for the Development of Bi-Specific and Multi-Specific Antibody Products PR Newswire
07:01AM  Compugen, AstraZeneca unit in cancer drug development deal Reuters
07:00AM  Compugen, AstraZeneca unit in cancer drug development deal Reuters
Mar-28-18 12:38PM  At $3.95, Is Compugen Ltd (NASDAQ:CGEN) A Buy? Simply Wall St.
Mar-26-18 07:00AM  Compugen Announces Appointment of Henry Adewoye, MD, as Chief Medical Officer PR Newswire
Mar-20-18 10:06AM  Compugen Ltd (NASDAQ:CGEN): Should The Future Outlook Worry You? Simply Wall St.
Mar-08-18 07:00AM  Compugen to Present at the Cowen and Company 38th Annual Health Care Conference PR Newswire
Feb-21-18 07:50AM  Compugen Ltd. to Host Earnings Call ACCESSWIRE +6.56%
07:31AM  Compugen reports 4Q loss Associated Press
07:07AM  Compugen Reports Fourth Quarter and Full Year 2017 Results PR Newswire
Feb-08-18 07:40AM  Wired News Compugen Reports Publication of Discovery and Validation of ILDR2 as A Novel Immune Checkpoint and Its Use for Auto-Immune Diseases ACCESSWIRE
07:00AM  Compugen Fourth Quarter and Full Year 2017 Conference Call Scheduled for Wednesday, February 21, 2018 at 10:00 AM ET PR Newswire
Feb-06-18 07:06AM  Compugen Announces Publication of the Discovery of ILDR2 as a Novel Immune Checkpoint and Its Use for the Treatment of Autoimmune Diseases in Two Back-to-Back Papers in The Journal of Immunology PR Newswire
Jan-18-18 07:00AM  Compugen Presents New Preclinical Data Demonstrating the Distinctive Features of the PVRIG Pathway in Immuno-Oncology and the Potential of COM701 for Treating Multiple Solid Tumors PR Newswire +18.18%
Jan-02-18 07:00AM  Compugen Announces Presentations at Three Upcoming Cancer Immunotherapy Conferences PR Newswire +8.00%
Dec-18-17 06:05PM  What You Must Know About Compugen Ltds (NASDAQ:CGEN) Financial Health Simply Wall St.
Dec-01-17 12:50PM  How Compugen Ltds (CGEN) EPS Dropped -53.2%, Did Its Industry Show Weakness Too? Simply Wall St.
Nov-15-17 12:37PM  Is It Too Late To Buy Compugen Ltd (CGEN)? Simply Wall St. +7.84%
Nov-07-17 08:20AM  Compugen Ltd. to Host Earnings Call ACCESSWIRE
07:17AM  Compugen reports 3Q loss Associated Press
07:10AM  Compugen Reports Third Quarter 2017 Results PR Newswire
Nov-06-17 09:23AM  Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers TheStreet.com
07:00AM  Compugen to Initiate Manufacturing of COM902, its Lead Anti-TIGIT Monoclonal Antibody PR Newswire
Nov-02-17 07:00AM  Compugen to Enter Research Collaboration With Mount Sinai on Novel Myeloid Immuno-Oncology Targets PR Newswire
Oct-26-17 07:00AM  Compugen to Present at the Annual Meeting of the Society for Immunotherapy of Cancer Next Month PR Newswire
Oct-25-17 07:00AM  Compugen Third Quarter 2017 Conference Call Scheduled for Tuesday, November 7, 2017 at 10:00 AM ET PR Newswire -5.80%
Oct-11-17 07:50AM  Corporate News Blog - Compugen Announces New Data Indicating Potential of CGEN-15032 ACCESSWIRE
Oct-10-17 08:30AM  Company News For Oct 10, 2017 Zacks
Oct-09-17 09:21AM  Flexion Shares Continue Rise After FDA Approval -- Biotech Movers TheStreet.com +7.04%
07:00AM  A New Immunomodulatory Target Discovered by Compugen Demonstrates Potential for First-in-Class Cancer Therapy PR Newswire
Oct-02-17 09:47AM  Compugen Ltd (CGEN): How Does It Impact Your Portfolio? Simply Wall St. -6.58%
Aug-07-17 07:00AM  Compugen to Present at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next Month PR Newswire
Aug-04-17 07:40AM  Corporate News Blog - Paul Sekhri Appointed Chairman of Board at Drug Discovery Company Compugen ACCESSWIRE
Aug-02-17 10:43PM  Compugen reports 2Q loss Associated Press
07:22AM  Compugen Welcomes Paul Sekhri as its New Chairman of the Board PR Newswire
07:20AM  Compugen Reports Second Quarter 2017 Results PR Newswire
Jul-26-17 07:09AM  Compugen Discloses Updates to Collaborative Activities with Bayer in Immuno-Oncology PR Newswire
Jul-25-17 07:00AM  Compugen Announces Issuance of U.S. Patent for COM701, its Lead Immuno-Oncology Product Candidate PR Newswire +19.12%
Jul-24-17 07:00AM  Compugen Second Quarter 2017 Conference Call Scheduled for Wednesday, August 2, 2017 at 10:00 AM ET PR Newswire
Jun-05-17 09:00AM  Compugen Presents at ASCO COM701 Drug Combination Data with TIGIT and PD-1 Inhibitors in Preclinical Models PR Newswire -6.45%
May-31-17 07:00AM  Compugen Provides Update on COM701 and Upcoming Presentations PR Newswire
May-25-17 07:06AM  Compugen Announces Appointment of Dr. Michal Preminger to Board of Directors PR Newswire
May-23-17 07:00AM  Compugen to Present at Two Upcoming Investor Conferences in June PR Newswire
May-22-17 08:30AM  Compugen (CGEN) Worth a Look: Stock Adds 10.4% in Session Zacks +6.32%
May-09-17 09:15AM  Investor Network: Compugen Ltd. to Host Earnings Call Accesswire +8.22%
09:04AM  Compugen reports 1Q loss Associated Press
07:13AM  Compugen Reports First Quarter 2017 Results PR Newswire
May-04-17 07:00AM  Compugen to Present COM701 Checkpoint Product Candidate for Immuno-Oncology at ASCO PR Newswire
Apr-26-17 07:00AM  Compugen First Quarter 2017 Conference Call Scheduled for Tuesday, May 9, 2017 at 10:00 AM ET PR Newswire
Apr-25-17 03:27PM  ETFs with exposure to Compugen Ltd. : April 25, 2017 Capital Cube
Apr-07-17 04:08PM  ETFs with exposure to Compugen Ltd. : April 7, 2017 Capital Cube
Mar-28-17 07:14AM  Compugen Announces Lead Therapeutic Candidate COM902 for CGEN-15137/TIGIT Immuno-Oncology Program PR Newswire
Mar-22-17 07:00AM  Compugen to Present CGEN-15001 Autoimmune Product Candidate at Upcoming Conferences PR Newswire
Mar-20-17 08:58AM  Compugen Ltd. :CGEN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Capital Cube
08:58AM  Compugen Ltd. :CGEN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
Mar-14-17 02:51PM  Compugen Ltd. :CGEN-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Capital Cube
02:51PM  Compugen Ltd. :CGEN-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
Mar-08-17 07:00AM  Compugen Announces Addition of Prof. Miriam Merad to Its Scientific Advisory Board PR Newswire
Mar-02-17 07:00AM  Compugen Announces Presentations of COM701 Immuno-oncology Pipeline Product and Predictive Discovery Methodology for Novel Immune Checkpoints at AACR PR Newswire
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations. Its product pipeline consists of COM701, a monoclonal antibody designed to block the interaction of PVRIG with its cognate ligand, PVRL2; CGEN-15001T, an immuno-oncology therapeutic program for ILDR2; and COM902, a therapeutic antibody candidate for its TIGIT program. The company's pipeline also comprises therapeutic proteins include CGEN-15001, a fusion protein drug candidate for autoimmune diseases, including extracellular domain of ILDR2 and an IgG Fc domain. Compugen Ltd. has a clinical trial collaboration with Bristol-Myers Squibb Company to evaluate the safety of COM701 in combination with Bristol-Myers Squibb's programmed death-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. The company was incorporated in 1993 and is headquartered in Holon, Israel.